

DAFTAR PUSTAKA

- Alarcón, G. S., McGwin, G., Bertoli, A. M., Fessler, B. J., Calvo-Alén, J., Bastian, H. M., Vilá, L. M., & Reveille, J. D. (2007). Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). *Annals of the Rheumatic Diseases*, 66(9), 1168–1172. <https://doi.org/10.1136/ard.2006.068676>
- Angum, F., Khan, T., Kaler, J., Siddiqui, L., & Hussain, A. (2020). The Prevalence of Autoimmune Disorders in Women: A Narrative Review. *Cureus*, 12(5), e8094. <https://doi.org/10.7759/cureus.8094>
- Arronson, J. (2016). Corticosteroids—Glucocorticoids. In *Meyler's Side Effects of Drugs* (pp. 594–657). Elsevier. <https://doi.org/10.1016/B978-0-444-53717-1.00549-7>
- Badsha, H., & Edwards, C. J. (2003). Intravenous pulses of methylprednisolone for systemic lupus erythematosus. *Seminars in Arthritis and Rheumatism*, 32(6), 370–377. <https://doi.org/10.1053/sarh.2002.50003>
- Barker, H. L., Morrison, D., Llano, A., Sainsbury, C. A. R., & Jones, G. C. (2023). Practical Guide to Glucocorticoid Induced Hyperglycaemia and Diabetes. *Diabetes Therapy*, 14(5), 937–945. <https://doi.org/10.1007/s13300-023-01393-6>
- Bashal, F. (2013). *Gangguan Hematologi pada Pasien Lupus Eritematosus Sistemik*. <https://doi.org/10.2174/1874312901307010087>
- Brady, V. J., Grimes, D., Armstrong, T., & LoBiondo-Wood, G. (2014). Management of steroid-induced hyperglycemia in hospitalized patients with cancer: A review. *Oncology Nursing Forum*, 41(6), E355-365. <https://doi.org/10.1188/14.ONF.E355-E365>
- CDC. (2023, January 31). *Systemic lupuserythematosus (SLE)*. Centers for Disease Control and Prevention. <https://www.cdc.gov/lupus/facts/detailed.html>
- Ceccarelli, F., Govoni, M., Piga, M., Cassone, G., Cantatore, F. P., Olivieri, G., Cauli, A., Favalli, E. G., Atzeni, F., Gremese, E., Iannone, F., Caporali, R., Sebastiani, M., Ferraccioli, G. F., Lapadula, G., & Conti, F. (2022). Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium. *Journal of Clinical Medicine*, 11(20), 6016. <https://doi.org/10.3390/jcm11206016>

Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., Fernández-Nebro, A., Galeazzi, M., Valen, M., Mathieu, A., Houssiau, F., Caro, N., Alba, P., Ramos-Casals, M., Ingelmo, M., ... European Working Party on Systemic Lupus Erythematosus. (2003). Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine*, 82(5), 299–308. <https://doi.org/10.1097/01.md.00000091181.93122.55>

Czock, D., Keller, F., Rasche, F. M., & H?ussler, U. (2005). Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids: *Clinical Pharmacokinetics*, 44(1), 61–98. <https://doi.org/10.2165/00003088-200544010-00003>

Deutsch, A. J., Schroeder, P. H., Mandla, R., Kang, S., Erenler, F., Mercader, J. M., Udler, M. S., Florez, J. C., & Brenner, L. N. (2023). Type 2 Diabetes Polygenic Score Predicts the Risk of Glucocorticoid-Induced Hyperglycemia in Patients Without Diabetes. *Diabetes Care*, 46(8), 1541–1545. <https://doi.org/10.2337/dc23-0353>

Diamond, B., & Lipsky, P. E. (2022). Autoimmunity and Autoimmune Diseases. In J. Loscalzo, A. Fauci, D. Kasper, S. Hauser, D. Longo, & J. L. Jameson (Eds.), *Harrison's Principles of Internal Medicine* (21st ed., pp. 2510–2515). McGraw-Hill Education. accessmedicine.mhmedical.com/content.aspx?aid=1198713717

Donihi, A. C., Raval, D., Saul, M., Korytkowski, M. T., & DeVita, M. A. (2006). Prevalence and Predictors of Corticosteroid-Related Hyperglycemia in Hospitalized Patients. *Endocrine Practice*, 12(4), 358–362. <https://doi.org/10.4158/EP.12.4.358>

Etchegaray-Morales, I., Mendoza-Pinto, C., Munguía-Realpozo, P., Solis-Poblano, J. C., Méndez-Martínez, S., Ayón-Aguilar, J., Abud-Mendoza, C., García-Carrasco, M., & Cervera, R. (2024). Risk of diabetes mellitus in systemic lupus erythematosus: Systematic review and meta-analysis. *Rheumatology*, keae204. <https://doi.org/10.1093/rheumatology/keae204>

Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S.-C., Boletis, J., Bruce, I. N., Cervera, R., Doria, A., Dörner, T., Furie, R. A., Gladman, D. D., Houssiau, F. A., Inês, L. S., Jayne, D., Kouloumas, M., Kovács, L., Mok, C. C., ... Boumpas, D. T. (2024). EULAR recommendations for the management of systemic lupus erythematosus:

2023 update. *Annals of the Rheumatic Diseases*, 83(1), 15–29.
<https://doi.org/10.1136/ard-2023-224762>

Gonzalez-Gonzalez, J. G., Mireles-Zavala, L. G., Rodriguez-Gutierrez, R., Gomez-Almaguer, D., Lavalle-Gonzalez, F. J., Tamez-Perez, H. E., Gonzalez-Saldivar, G., & Villarreal-Perez, J. Z. (2013). Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients. *Diabetology & Metabolic Syndrome*, 5, 18. <https://doi.org/10.1186/1758-5996-5-18>

Ha, Y., Lee, K.-H., Jung, S., Lee, S.-W., Lee, S.-K., & Park, Y.-B. (2011). Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. *Lupus*, 20(10), 1027–1034. <https://doi.org/10.1177/0961203311402246>

Han, S. (2015). Clinical pharmacology review for primary health care providers: II. Steroids. *Translational and Clinical Pharmacology*, 23(1), 15. <https://doi.org/10.12793/tcp.2015.23.1.15>

Héacute, Tamez-Péacute, ctor E., Rez, D. L. Q.-F., Rodríacute, guez-Gutiéacute, Rrez, J., Gonzáacute, G., lez-Gonzáacute, & Lez, A. L. T.-P. (2015). Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. *World Journal of Diabetes*, 6(8), 1073–1081. <https://doi.org/10.4239/wjd.v6.i8.1073>

Hwang, J. L., & Weiss, R. E. (2014). Steroid-induced diabetes: A clinical and molecular approach to understanding and treatment. *Diabetes/Metabolism Research and Reviews*, 30(2), 96–102. <https://doi.org/10.1002/dmrr.2486>

Infodatin-Lupus-2017.pdf. (n.d.). Retrieved April 3, 2023, from <https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/Infodatin-Lupus-2017.pdf>

Katsuyama, T., Sada, K.-E., Namba, S., Watanabe, H., Katsuyama, E., Yamanari, T., Wada, J., & Makino, H. (2015). Risk factors for the development of glucocorticoid-induced diabetes mellitus. *Diabetes Research and Clinical Practice*, 108(2), 273–279. <https://doi.org/10.1016/j.diabres.2015.02.010>

Kim, M.-J., Lim, N.-K., Choi, S.-J., & Park, H.-Y. (2015). Hypertension is an independent risk factor for type 2 diabetes: The Korean genome and epidemiology study. *Hypertension Research*, 38(11), 783–789. <https://doi.org/10.1038/hr.2015.72>

- Kim, S. Y., Yoo, C.-G., Lee, C. T., Chung, H. S., Kim, Y. W., Han, S. K., Shim, Y.-S., & Yim, J.-J. (2011). Incidence and Risk Factors of Steroid-induced Diabetes in Patients with Respiratory Disease. *Journal of Korean Medical Science*, 26(2), 264. <https://doi.org/10.3346/jkms.2011.26.2.264>
- Li, J.-X., & Cummins, C. L. (2022). Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. *Nature Reviews Endocrinology*, 18(9), 540–557. <https://doi.org/10.1038/s41574-022-00683-6>
- Lin, Y.-J., Chien, C.-C., Ho, C.-H., Chen, H.-A., & Chen, C.-Y. (2022). Increased risk of type 2 diabetes in patients with systemic lupus erythematosus: A nationwide cohort study in Taiwan. *Medicine*, 101(51), e32520. <https://doi.org/10.1097/MD.00000000000032520>
- Mariska, I. K. N. & A. F. (2020). ASSOCIATION BETWEEN AGES AND GLUCOCORTICOID-INDUCED DIABETES MELLITUS INCIDENCE IN INTRACRANIAL TUMOR PATIENTS. *International Journal of Research Science and Management*, 7(7), Article 7.
- Nakamura, H., Fujieda, Y., Nakamura, A., & Atsumi, T. (2021). How should rheumatologists manage glucocorticoid-induced hyperglycemia? *Modern Rheumatology*, 31(3), 519–528. <https://doi.org/10.1080/14397595.2020.1823060>
- NEWS, U. (2022, November 28). *Beban Biaya Medis Pasien Diabetes Melitus Dengan Komplikasi di Sebuah Rumah Sakit Di Surabaya*. Universitas Airlangga Official Website. <https://unair.ac.id/beban-biaya-medis-pasien-diabetes-melitus-dengan-komplikasi-di-sebuah-rumah-sakit-di-surabaya/>
- Østensen, M., & Villiger, P. M. (2001). Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. *Lupus*, 10(3), 135–139. <https://doi.org/10.1191/096120301668183556>
- Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *The Canadian Journal of Cardiology*, 34(5), 575–584. <https://doi.org/10.1016/j.cjca.2017.12.005>
- Pons-Estel, G. J., Ugarte-Gil, M. F., & Alarcón, G. S. (2017). Epidemiology of systemic lupus erythematosus. *Expert Review of Clinical Immunology*, 13(8), 799–814. <https://doi.org/10.1080/1744666X.2017.1327352>

- Porta, S., Danza, A., Arias Saavedra, M., Carlomagno, A., Goizueta, M. C., Vivero, F., & Ruiz-Irastorza, G. (2020). Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. *Journal of Clinical Medicine*, 9(9), 2709. <https://doi.org/10.3390/jcm9092709>
- Rana, M. A., H. Siddiqui, M., Raza, S., Tehreem, K., Mahmood, M. F. U., Javed, M., Qayyum, M. A., & Hafeez, M. M. (2021). Incidence of Steroid-induced Diabetes in COVID-19 patients. *Pakistan Journal of Medical and Health Sciences*, 15(10), 2595–2596. <https://doi.org/10.53350/pjmhs2115102595>
- Rhou, Y. J. J., Hor, A., Wang, M., Wu, Y.-F., Jose, S., Chipps, D. R., & Cheung, N. W. (2022). Dexamethasone-induced hyperglycaemia in COVID-19: Glycaemic profile in patients without diabetes and factors associated with hyperglycaemia. *Diabetes Research and Clinical Practice*, 194, 110151. <https://doi.org/10.1016/j.diabres.2022.110151>
- Ruiz-Irastorza, G., & Bertsias, G. (2020). Treating systemic lupus erythematosus in the 21st century: New drugs and new perspectives on old drugs. *Rheumatology (Oxford, England)*, 59(Suppl 5), v69–v81. <https://doi.org/10.1093/rheumatology/keaa403>
- Sendrasoa, F. A., Ranaivo, I. M., Raherivelo, A. J., Rapelanoro Rabenja, F., & Ramarozatovo, L. S. (2021). Adverse Effects of Long-Term Oral Corticosteroids in the Department of Dermatology, Antananarivo, Madagascar. *Clinical, Cosmetic and Investigational Dermatology, Volume 14*, 1337–1341. <https://doi.org/10.2147/CCID.S332201>
- Shaharir, S. S., Gafor, A. H. A., Said, M. S. M., & Kong, N. C. T. (2015). Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: Analysis from a Malaysian multi-ethnic lupus cohort. *International Journal of Rheumatic Diseases*, 18(5), 541–547. <https://doi.org/10.1111/1756-185X.12474>
- Suh, S., & Park, M. K. (2017). Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. *Endocrinology and Metabolism*, 32(2), 180–189. <https://doi.org/10.3803/EnM.2017.32.2.180>
- Sumariyono, Kalim H, Setyohadi B, et al. (2019). *Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik – Perhimpunan Reumatologi Indonesia*. <https://reumatologi.or.id/diagnosis-dan-pengelolaan-lupus-eritematosus-sistemik/>

Uzu, T., Harada, T., Sakaguchi, M., Kanasaki, M., Isshiki, K., Araki, S., Sugimoto, T., Koya, D., Haneda, M., Kashiwagi, A., & Yamauchi, A. (2006). Glucocorticoid-Induced Diabetes Mellitus: Prevalence and Risk Factors in Primary Renal Diseases. *Nephron Clinical Practice*, 105(2), c54–c57. <https://doi.org/10.1159/000097598>

van Raalte, D. H., & Diamant, M. (2014). Steroid diabetes: From mechanism to treatment? *The Netherlands Journal of Medicine*, 72(2), 62–72.

Wang, Y., Hester, L. L., Lofland, J., Rose, S., Karyekar, C. S., Kern, D. M., Blacketer, M., Davis, K., & Shields-Tuttle, K. (2022). Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016. *BMC Research Notes*, 15(1), 5. <https://doi.org/10.1186/s13104-021-05877-1>

Widyanrika, F. A., Mudjanarko, S. W., Rochmanti, M., Ardiany, D., & Permana, P. B. D. (2024). Association between the Duration of Steroid Therapy with Hyperglycemia in Patients with Systemic Lupus Erythematosus (SLE). *Current Internal Medicine Research and Practice Surabaya Journal*, 5(1), Article 1. <https://doi.org/10.20473/cimrj.v5i1.53043>

Yanih, I. (2016). Quality of Life in Patient with Systemic Lupus Erythematosus (SLE). *Jurnal Berkala Epidemiologi*, 4, 1. <https://doi.org/10.20473/jbe.v4i1.2016.1-12>

Yazdany, J., & Dall'Era, M. (2019). Definition and Classification of Lupus and Lupus-Related Disorders. In *Dubois' Lupus Erythematosus and Related Syndromes* (pp. 15–22). Elsevier. <https://doi.org/10.1016/B978-0-323-47927-1.00002-5>

Zabihi Yeganeh, M., & Sadeghi, S. (2013). Risk Factors of Glucocorticoid-Induced Diabetes Mellitus in Systemic Lupus Erythematosus. *Galen Medical Journal*, 2(2), 39–43. <https://doi.org/10.31661/gmj.v2i2.51>

LAMPIRAN

Lampiran 1. Surat Ethical Clearance